StockData
Vicapsys Life Sciences, Inc. logo

Vicapsys Life Sciences, Inc. (VICP) stock

VICPOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2024, quý kết thúc ngày Sep 30, 2024Last filing: 10-Q on Jan 10, 2025
$0.40+0.00 (0.00%)

Close on Oct 19, 2026Market cap $13.73MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2024

Valuation

Market cap
$13.73M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$1.35M
EPS, diluted
-$0.05
Book value per share
-$0.08
Diluted shares
34M

Trading

Previous close
$0.40
Open
$0.40
Day's range
$0.40 – $0.40
Volume
0
Average volume (20 days)
4,245

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodVICPS&P 500DifferenceVICP per yearS&P 500 per year
1 month-52.9%+0.6%−53.6 pts
3 months-72.6%+3.4%−76.0 pts
Year to date-73.3%+13.3%−86.6 pts
1 year-77.4%+16.6%−94.0 pts
3 years-86.7%+86.4%−173.0 pts-48.9%+23.1%
5 years+60.0%+81.9%−21.9 pts+9.9%+12.7%
10 years-60.0%+318.9%−378.9 pts-8.8%+15.4%

Six years at a glance

Fiscal years 2018 to 2023 and trailing twelve months, USD

Operating income

-$1.11M

Net income

-$1.35M

EPS, diluted

-$0.05
Reported periodTrailing twelve months

Press releases

Releases Vicapsys Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K

About Vicapsys Life Sciences

Pharmaceutical Preparations

Vicapsys Life Sciences, Inc. is a preclinical biotechnology company focused on developing and commercializing therapeutic technologies that create zones of immunoprotection. Utilizing proprietary derivatives of the chemokine CXCL12 licensed from Massachusetts General Hospital, the company designs encapsulated product candidates to shield transplanted cells, tissues, organs, and medical devices from immune destruction and fibrotic encapsulation. Its development pipeline includes VICAPSYN, an encapsulated human islet cell cluster designed for transplantation therapies to treat patients suffering from Type 1 diabetes, and VYBRIN, an anti-fibrotic product candidate being explored to prevent post-surgical abdominal adhesions, coat implantable medical devices, and promote diabetic ulcer wound healing.

Company profile, executives and history

Vicapsys Life Sciences stock: common questions

What is Vicapsys Life Sciences's stock price?

VICP closed at $0.40 on Oct 19, 2026, up 0.00% on the day.

What is Vicapsys Life Sciences's market cap?

Vicapsys Life Sciences was worth $13.73M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is VICP's P/E ratio?

Vicapsys Life Sciences lost money over the twelve months to Sep 30, 2024 (diluted EPS -$0.05), so it has no meaningful P/E ratio.

Does Vicapsys Life Sciences pay a dividend?

No. Vicapsys Life Sciences has not paid a cash dividend over the last twelve months.

How has VICP stock performed over the past year?

Including dividends, VICP returned -77.4% over the past year, against +16.6% for the S&P 500.

Who are Vicapsys Life Sciences's competitors?

Companies most similar to Vicapsys Life Sciences by business, industry and size include BIXT, FBLG, ELDN, GALT, SKYE.

See a number that looks wrong?